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Summary
The oncogene c-maf is translocated in 5%–10% of multiple myelomas. Unexpectedly, we observed c-maf expression in
myeloma cell lines lacking c-maf translocations and in 50% of multiple myeloma bone marrow samples. By gene expression
profiling, we identified three c-maf target genes: cyclin D2, integrin 7, and CCR1. c-maf transactivated the cyclin D2
promoter and enhanced myeloma proliferation, whereas dominant inhibition of c-maf blocked tumor formation in immunode-
ficient mice. c-maf-driven expression of integrin 7 enhanced myeloma adhesion to bone marrow stroma and increased
production of VEGF. We propose that c-maf transforms plasma cells by stimulating cell cycle progression and by altering
bone marrow stromal interactions. The frequent overexpression of c-maf in myeloma makes it an attractive target for
therapeutic intervention.
Introduction Recent work has also demonstrated that interaction of my-
eloma cells with bone marrow stroma provides the cells with
Multiple myeloma, an incurable malignancy of the plasma cell, growth and survival factors such as IL-6 and VEGF and pro-
accounts for roughly 20% of all hematological malignancies. motes chemotherapeutic drug resistance (Dalton, 2002; Hides-
Clues to the pathogenesis of myeloma are coming from two hima and Anderson, 2002). Although a number of adhesion
general approaches, one that focuses on recurrent transloca- molecules are present on the surface of multiple myeloma cells,
tions and mutations of oncogenes and the other that empha- it is not clear which are critical for binding to stromal cells (Cook
sizes the interplay between the malignant plasma cells and the et al., 1997).
bone marrow microenvironment (Kuehl and Bergsagel, 2002). In the present study, we investigated how the oncogene
Four recurrent translocations involving the immunoglobulin c-maf contributes to the pathogenesis of multiple myeloma.
heavy chain (IgH) locus are likely to be primary oncogenic events c-maf is a member of the basic-leucine zipper family of tran-
based on their occurrence in a premalignant lesion termed
scription factors that has been shown to be important for IL-4monoclonal gammopathy of undetermined significance (MGUS)
gene expression by T-helper-2 cells (Ho et al., 1996; Kim et al.,(Fonseca et al., 2002), and their use of illegitimate IgH switch
1999a), and formation of the lens (Kim et al., 1999b). To date,recombination (Kuehl and Bergsagel, 2002). The t(11;14) and
the molecular targets of c-maf transactivation that are importantt(6;14) translocations involve the cyclin D1 and cyclin D3 genes,
for malignant transformation in multiple myeloma have not beenrespectively, and presumably disturb the physiological exit of
elucidated. In the present study, we used gene expression pro-plasma cells from the cell cycle. The t(4;14) translocation dereg-
filing to identify cyclin D2 and integrin 7 as c-maf target genesulates both the FGFR3 and MMSET genes and the t(14;16)
in multiple myeloma, and demonstrate that c-maf increasestranslocation deregulates the c-maf gene, but the functional
consequences of these translocations are unknown. myeloma proliferation and adhesion to bone marrow stroma.
S I G N I F I C A N C E
Recurrent translocations have been identified in multiple myeloma, but their functional significance is largely unknown. Unexpectedly,
we found that roughly 50% of myelomas overexpress the oncogene c-maf, although c-maf translocations occur in only 5%–10% of
cases. c-maf increased the expression of cyclin D2 and integrin 7, leading to enhanced proliferation and increased adhesion to
bone marrow stroma. Inhibition of c-maf function potently blocked tumor formation in immunodeficient mice, suggesting that c-maf
is an attractive therapeutic target for roughly one half of myeloma patients.
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Notably, we found c-maf to be overexpressed and functional into one cell line that expresses c-maf as a consequence of a
in roughly one half of myelomas, leading us to propose that t(14;16) translocation (JJN3) (Chesi et al., 1998). The three genes
c-maf is an attractive therapeutic target in this malignancy. that were consistently upregulated by c-maf overexpression
and downregulated by Ac-maf were again integrin 7, cyclin
Results D2, and CCR1, thus confirming that these genes are under
the control of c-maf (Figure 2A). No genes were consistently
Identification of c-maf target genes repressed by c-maf or induced by Ac-maf (data not shown).
To gain insight into the mechanism of action of multiple myeloma Ac-maf had no effect on gene expression in two cell lines that
oncogenes, we used DNA microarrays to profile gene expres- do not express c-maf (L363 and KMS12; Figure 2A), demonstra-
sion in a panel of 28 multiple myeloma cell lines that have been ting the specificity of this dominant negative protein for c-maf.
extensively characterized with respect to translocations, gene As expected from the changes in mRNA abundance, overex-
copy number changes, and oncogene mutations (Bergsagel et pression of c-maf increased cyclin D2 and integrin 7 protein
al., 1996). Cell lines with translocations of the cyclin D1 and levels (Figures 2C and 2D) and Ac-maf decreased integrin 7
MMSET/FGFR3 genes expressed these genes more highly than protein levels in c-maf-positive cells (Figure 2D).
cell lines lacking these translocations (data not shown). Unex- To confirm that these target genes are downstream of c-maf
pectedly, c-maf was not only expressed in the 6 cell lines with action, we used siRNA to reduce expression of c-maf mRNA
c-maf translocations, but also in cell lines lacking this transloca- in H929 cells. Quantitative RT-PCR confirmed that c-maf, integ-
tion (data not shown). To confirm and extend this observation, rin 7, cyclin D2, and C-C chemokine receptor-1 (CCR1) mRNAs
we measured c-maf mRNA levels using a quantitative RT-PCR were knocked down by c-maf siRNA in H929 cells (Figure 2B).
assay in the 28 cell lines (Figure 1A). We found that 13 (46%) c-maf siRNA transduction also decreased surface expression
expressed high levels, 3 (11%) expressed low levels, and the of integrin 7 (Figure 2D).
remainder had no detectable c-maf expression. Although c-maf The cyclin D2 promoter contains a potential c-maf binding
expression varied over a wide range, some cell lines lacking a site that matches the consensus c-maf binding (MARE) motif
c-maf translocation expressed c-maf as highly as some with and is well conserved in the human and mouse orthologs (Figure
a c-maf translocation. It is interesting to note that c-maf is 2C). c-maf was able to directly transactivate a cyclin D2 pro-
overexpressed in all cell lines with an MMSET/FFGR3 transloca- moter construct in transient transfection assays (Figure 2C). A
tion and one cell line with a cyclin D1 translocation. We also 7 bp mutation that disrupts the key c-maf contact nucleotides
detected frequent c-maf expression in primary multiple my-
of the MARE motif abrogated the ability of c-maf to transactivate
eloma cells purified from patient bone marrow aspirates (13/26
the cyclin D2 promoter (Figure 2C). These observations provide
samples; 50%) (Figure 1A), which was surprising since c-maf
evidence that cyclin D2 is a direct target of c-maf transactivation.
translocations occur in only 5%–10% of myeloma cases (Kuehl
and Bergsagel, 2002). c-maf mRNA was undetectable in normal
c-maf augments myeloma proliferationplasma cells purified from bone marrow aspirates, demonstra-
and tumor formationting that c-maf overexpression in multiple myeloma is associ-
Since c-maf increased cyclin D2 protein levels (Figure 2C), weated with the malignant process (Figure 1A).
investigated whether c-maf affected cell cycle progression. Ret-To discover potential c-maf target genes, we searched the
roviral transduction of c-maf into myeloma cells lacking endoge-myeloma cell line gene expression dataset for genes that were
nous c-maf expression caused these already cycling cells todifferentially expressed between c-maf-expressing and -nonex-
increase their division and DNA synthesis (Figure 3A). We ob-pressing cell lines. The three genes that satisfied the selection
served no evidence of increased cell death induced by dominantcriteria (p  0.001; t test) were integrin 7, cyclin D2, and C-C
negative c-maf (data not shown). This finding is consistent withchemokine receptor-1 (CCR1) (Figure 1B). Even cell lines with
the idea that the c-maf-driven increase in cyclin D2 levels aug-relatively low c-maf expression (e.g., XG-2) expressed these
ments entry of cells into the cell cycle. Conversely, in most (6/7)putative c-maf target genes at higher levels than c-maf-negative
c-maf expressing myeloma cell lines, introduction of Ac-mafcell lines (Figure 1B). We confirmed the coregulation of c-maf
decreased their division, including cell lines with and without aand integrin 7 in the myeloma cell lines by quantitative RT-
c-maf translocation (Figure 3B). As expected, Ac-maf had noPCR, and also observed this coregulation in the primary multiple
effect on the proliferation of two c-maf negative cell lines (Figuremyeloma samples (Figure 1A). Although a few myeloma cell
3B), again confirming the specificity of this dominant negativelines lacking c-maf expression had low levels of integrin 7
protein for c-maf.mRNA, patient samples and normal bone marrow plasma cells
Given the effect of c-maf on proliferation in vitro, we testedlacking c-maf expression did not express integrin 7 detectably
whether tumor formation in vivo by c-maf-expressing myelomas(Figure 1A).
was dependent on c-maf (Figure 4). NOD-SCID immunodefi-To directly search for c-maf target genes, we manipulated
cient mice were injected intraperitoneally with LP-1 cells thatthe activity of c-maf in myeloma cell lines and profiled the resul-
had been transduced with a retrovirus expressing dominanttant changes in gene expression. Using retroviral transduction,
negative Ac-maf or with a control retrovirus. Tumor formationwe overexpressed c-maf in two cell lines that have no endoge-
was assessed by measuring human immunoglobulin in thenous c-maf expression (KMS12 and L363). Additionally, we cre-
blood and by the appearance of visible abdominal masses (Fig-ated a dominant negative form of c-maf, termed Ac-maf, by
ures 4A and 4B). All four mice injected with the control LP-1replacing the basic DNA binding region of c-maf with an acidic
cells developed tumors within 26–36 days and had rapidly risingregion while retaining the leucine zipper (Olive et al., 1997). We
titers of human immunoglobulin in their blood (Figures 4A andused retroviruses to transduce Ac-maf into two cell lines that
express c-maf without a translocation (H929 and LP-1), and 4B). By contrast, the mice injected with dominant negative Ac-
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Figure 1. Frequent overexpression of c-maf and coregulated genes in multiple myeloma cell lines and patient samples
A: Expression levels of c-maf and integrin 7 in myeloma cell lines, myeloma patient samples, and normal bone marrow plasma cells as determined by a
quantitative reverse transcription polymerase chain reaction assay.
B: Genes coregulated with c-maf in multiple myeloma cell lines. Gene expression was assessed by quantitative RT-PCR (c-maf) or DNA microarray
measurements (integrin 7, cyclin D2, CCR1). Relative gene expression levels are depicted according to the color scale shown in which shades of red
indicate higher expression and shades of green indicate lower expression. Gray indicates missing data.
maf LP-1 cells either did not form tumors (2/4) or formed tumors c-maf increases myeloma adhesion
to bone marrow stromaat a later time point than the mice with control LP-1 cells (Figure
4B). Interestingly, the two tumors that arose in mice receiving Since the interaction of the bone marrow stroma with multiple
myeloma cells is an important component of the pathophysiol-Ac-maf LP-1 cells had little or no expression of Ac-maf protein
at the time of sacrifice, unlike the cells that were originally in- ogy of this malignancy (Anderson, 2001; Shain et al., 2000), we
asked whether the upregulation of integrin 7 by c-maf alteredjected in these animals (Figure 4C). The emergence of these
escape tumors, together with the fact that Ac-maf prevented the adhesion properties of myeloma cells. Integrin 7 can het-
erodimerize with either integrin 4 or integrin E. Integrin 47tumor formation altogether in 2/4 mice, provides evidence that
inhibition of c-maf function blocks the in vivo proliferation of binds to MadCAM-1 and integrin E7 binds to E-cadherin
(Hynes, 2002). E-cadherin has been detected on the surface ofc-maf-expressing myelomas.
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Figure 2. c-maf regulates the expression of integrin 7, cyclin D2, and CCR1 and activates the cyclin D2 promoter
A: c-maf function in myeloma cell lines was manipulated by retroviral transduction of c-maf or a dominant negative form of c-maf. Gene expression
changes are depicted according to the color scale in which red indicates an increase, green indicates a decrease, and black indicates no change.
Gray indicates missing data. Multiple microarray elements are shown for each target gene.
B: Quantitative RT-PCR assay for c-maf, integrin 7, cyclin D2, and C-C chemokine receptor-1 mRNA of H929 cells 72 hr after being transduced with a
c-maf siRNA oligonucleotide.
C: c-maf overexpression increases cyclin D2 protein levels. Western blot analysis of L363 cells that have been transduced with a retrovirus expressing c-maf
or a control retrovirus is shown. -tubulin serves as a loading control. Also shown is the regulation of the cyclin D2 promoter by c-maf. KMS12 myeloma cells
were transfected with a c-maf expression construct or a control vector together with a luciferase reporter construct driven by either a wild-type or mutant
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Figure 3. c-maf overexpression promotes prolif-
eration in myeloma cell lines while dominant
negative inhibition of c-maf retards proliferation
A: Overexpression of c-maf enhances prolifera-
tion and DNA synthesis. Growth curves of two
myeloma cell lines lacking endogenous c-maf
expression (L363 and KMS12) that have been
transduced with a retrovirus expressing c-maf or
a control retrovirus. An average of two experi-
ments preformed in triplicate is shown with error
bars representing the standard deviation. Also
shown is the incorporation of H3-thymidine into
DNA in KMS12 cells transduced with a c-maf ex-
pressing retrovirus or a control retrovirus.
B: Inhibition of c-maf reduces the proliferation of
c-maf-expressing cell myeloma cells. Retrovi-
ruses expressing a dominant negative form of
c-maf and GFP from a bicistronic mRNA, or GFP
alone were used to infect the indicated cell lines.
The number of GFP live cells in the cultures over
time were determined relative to the number at
day 2 following retroviral transduction.
bone marrow stromal cells (Turel and Rao, 1998). Two cell lines myeloma proliferation and survival, and may induce neovascu-
larization (Bellamy et al., 1999; Dankbar et al., 2000; Gupta etthat express endogenous c-maf (H929 and LP-1) adhered to
al., 2001; Podar et al., 2001, 2002). We therefore investigatedE-cadherin-coated plates, whereas two cell lines lacking c-maf
whether the enhanced stromal interaction caused by c-maf re-expression (L363 and KMS12) did not bind to E-cadherin-coated
sults in increased VEGF secretion (Figure 5E). Myeloma cellsplates (Figure 5A). Retroviral transduction of c-maf into these
and stroma cells alone did not secrete appreciable quantitieslatter cell lines conferred binding to E-cadherin-coated plates
of VEGF, but cocultures of stroma with myeloma cells lacking(Figure 5A).
c-maf expression produced more VEGF (2.3-fold). Even greaterNext we investigated the role of c-maf in the interaction of
VEGF secretion (5.5-fold) occurred in cocultures of stroma withmyeloma cells with bone marrow stromal cells (Figure 5B). Cell
c-maf-expressing myeloma cells. Again, this augmented VEGFlines expressing c-maf were able to adhere to the stroma, pre-
production was dependent upon integrin E7 interactions withsumably through the concerted action of several adhesion mole-
E-cadherin since antibodies to these two adhesion proteinscules (Anderson, 2001; Shain et al., 2000). Preincubation of the
reduced VEGF secretion to the levels observed using c-mafmyeloma cells with an anti-integrin 7 antibody resulted in a
nonexpressing myeloma cells. These data suggest that c-maf40%–72% decrease in adherence to the stroma (Figure 5B).
alters the nature of the myeloma/stromal cell interaction andPreincubation of the stroma with an E-cadherin antibody
that interaction leads to an increase in VEGF secretion.blocked adherence of myeloma cells to a similar degree (Figure
5B). Myeloma cell lines lacking c-maf expression were able to
adhere to stroma, but transduction of these cells with the c-maf Discussion
retrovirus increased adherence 2.5- to 3.5-fold (Figure 5C). Anti-
bodies to integrin 7 or E-cadherin completely blocked the The present analysis of c-maf transcriptional targets in multiple
myeloma suggests that c-maf may promote malignant transfor-increased adherence caused by c-maf (Figure 5C). We devel-
oped a competitive binding assay in which fluorescently labeled, mation of plasma cells by at least two distinct mechanisms
(Figure 6). One mechanism involves the enhanced proliferationc-maf-negative cells were allowed to adhere to stroma in the
presence of increasing numbers of unlabeled cells; c-maf- of myeloma cells in a cell autonomous fashion. Plasmacytic
differentiation is accompanied by upregulation of the cyclin-expressing cells were more efficient competitors than cells lack-
ing c-maf (Figure 5D). These data suggest that c-maf enhances dependent kinase inhibitor, p18 (Tourigny et al., 2002). Myelo-
mas apparently must circumvent this physiological cell cyclethe adhesion of myeloma cells to bone marrow stroma through
interactions between integrin E7 and E-cadherin. arrest since two recurrent translocations in myeloma involve the
cyclin D1 and cyclin D3 genes, and homozygous deletions ofInteraction of myeloma cells with bone marrow stroma in-
duces secretion of vascular endothelial growth factor (VEGF), the p18 locus can occur (Kulkarni et al., 2002). Our results
suggest that the transcriptional activation of cyclin D2 by c-mafwhich may act in an autocrine and paracrine fashion to promote
cyclin D2 promoter. Luciferase activity is indicated as an average of triplicate assays from two independent experiments, with error bars representing the
standard deviation. The conserved c-maf binding motif (MARE) in the promoter regions of the human and mouse cyclin D2 gene is shown together with
the mutated nucleotides of the mutant cyclin D2 construct. The MARE is located between 134 and 122 with respect to the start of translation in the
human gene.
D: Surface expression of integrin 7 is shown for cell lines infected with retroviruses expressing either c-maf or a dominant negative form of c-maf. Surface
integrin 7 is also shown for H929 cells 72 hr after being transduced with a c-maf siRNA construct.
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Figure 4. Inhibition of c-maf blocks tumor forma-
tion in immunodeficient mice
c-maf-expressing LP-1 cells were transduced
with a retrovirus expressing dominant negative
Ac-maf or a control retrovirus and injected intra-
peritoneally into NOD-SCID mice.
A: Human immunoglobulin levels in blood as as-
sessed by ELISA.
B: Occurrence of palpable tumors.
C: Western blot analysis of tumors formed in mice
injected with Ac-maf-transduced myeloma
cells.
provides another mechanism promoting cell cycle progression Whereas most oncogenes render the tumor cell independent
of external signals for proliferation and survival (Hanahan andin myeloma. The fact that all three D type cyclins are overex-
pressed in myeloma by disparate mechanisms suggests that Weinberg, 2000), c-maf defines a class of oncogenes that en-
hance interactions between stromal cells and tumor cells (Figureforced progression through G1/S phase of the cell cycle is an
important and frequent oncogenic event in multiple myeloma. 6). This class of oncogenes was predicted to exist (Hanahan
Figure 5. c-maf expression enhances adhesion
to E-cadherin and bone marrow stroma
A: Binding of myeloma cell lines expressing c-maf
either endogenously or as a result of retroviral
transduction to E-cadherin coated plates.
B: Binding of multiple myeloma cell lines express-
ing endogenous c-maf to bone marrow stroma.
The effect of antibodies to integrin 7 and
E-cadherin is compared to control IgG1.
C: Binding of myeloma cell lines that lack expres-
sion of endogenous c-maf to bone marrow
stroma after infection with a retrovirus expressing
c-maf or with a control retrovirus. The effect of
antibodies to integrin 7 and E-cadherin is com-
pared to control IgG1.
D: Competitive binding assay of myeloma cells
to bone marrow stroma. c-maf-negative KMS12
cells were fluorescently labeled and allowed to
adhere to stroma in the presence of increasing
numbers of unlabeled competitor cells that do
or do not express c-maf, as indicated.
E: Secretion of VEGF by KMS12 myeloma cells
transduced with control or c-maf-expressing re-
troviruses, bone marrow stromal cells, or cocul-
tures of myeloma and stromal cells. All assays
were done in triplicate and error bars indicate
the standard deviation.
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Our results thus identify c-maf overexpression as one of
the most frequent oncogenic events in multiple myeloma and
establish c-maf as an intriguing novel therapeutic target. Domi-
nant inhibition of c-maf interfered with stromal cell adhesion
and proliferation of myeloma cells with c-maf overexpression,
whether or not they had a c-maf translocation, and c-maf inhibi-
tion blocked tumor formation in immunodeficient mice. Our data
predict that an inhibitor of c-maf function would decrease cyclin
D2 expression, stromal cell adhesion, and VEGF secretion,
thereby inhibiting myeloma proliferation and survival.
Experimental procedures
Figure 6. A model by which c-maf overexpression may cause multiple my-
Gene expression profilingeloma
mRNA from cell lines was isolated using the FastTrack 2.0 kit (Invitrogen).
See text for details. Total RNA from patient samples was isolated using Trizol (GIBCO-BRL).
Lymphochip DNA microarrays were prepared, hybridized, and analyzed as
previously described (Shaffer et al., 2000). Relative gene expression was
assessed by comparing a myeloma cDNA probe (labeled with Cy5 dye) with
a reference cDNA probe (labeled with Cy3 dye) prepared from a pool of 9and Weinberg, 2000) since, in many cancers, tumor cells receive
lymphoid cell lines, as described (Shaffer et al., 2000). DNA microarray genegrowth and survival signals from stroma (Liotta and Kohn, 2001;
expression data were used to identify genes coregulated with c-maf byTlsty, 2001). c-maf translocations occur in MGUS (Fonseca et
comparing expression in c-maf-postive and c-maf-negative cell lines (as
al., 2002), a premalignant lesion characterized by abnormal ac- determined by quantitative RT-PCR), using a t test to assess statistical
cumulation of plasma cells, and thus c-maf influences early significance. Selection criteria for c-maf coregulation were p  0.001,
events in myeloma pathogenesis. Since bone marrow stromal variance  2.0, and 10% missing values. For direct identification of c-maf
target genes, Cy5-labeled cDNA probes were prepared from cells trans-cells are known to provide survival signals to plasma cells (Ka-
duced with retroviruses expressing c-maf or dominant negative c-maf andwano et al., 1995; Merville et al., 1996; Minges Wols et al., 2002;
compared with Cy3-labeled probes from cells transduced with a controlRoldan and Brieva, 1991), the enhanced adhesion of c-maf-
retrovirus. All gene expression data is available at http://lymphochip.nih.gov/
expressing MGUS cells to stroma may give them a selective hurtetal and as Supplemental Tables S1 and S2 at http://www.cancercell.
advantage over normal plasma cells in the bone marrow micro- org/cgi/content/full/5/2/191/DC1.
environment. Further, enhanced production of VEGF as a result
Quantitative reverse transcription polymeraseof integrin E7/E-cadherin interactions may function in an au-
chain reaction (RT-PCR)tocrine or paracrine fashion to promote myeloma proliferation
Flow sorting was used to purify plasma cells from bone marrow aspiratesand survival (Bellamy et al., 1999; Dankbar et al., 2000; Gupta
of myeloma patients (CD138, CD38, CD56) and from normal donor
et al., 2001; Podar et al., 2001, 2002). VEGF may also contribute bone marrow aspirates (CD138, CD38, CD19). Quantitative RT-PCR
to the enhanced bone marrow angiogenesis that is characteris- assays (TaqMan) were performed using a one-step reaction solution using
tic of myeloma (Anderson, 2001). the primers shown below for c-maf, integrin 7, and USF2 or using primers
provided by Assays-on-Demand (Applied Biosystems). The expression ofIn addition to affecting proliferation and adhesion, c-maf
USF2 was detected with the forward primer GGAGCGGCCTGCGATTT, themay also alter the function of myeloma cells by upregulating
reverse primer CTTTGAAGGTCTCCTGCATGC, and the probe TCCGGGAGCCR1, a receptor for the chemokine MIP-1. Indeed, ectopic
TTGCGCCAGACC. Integrin7 was detected with the forward primer GAAT
expression of c-maf in myeloma cells increased their chemo- CAACCAGACGGTGACTTTCT, the reverse primer GCCCGGAGCCTCA
taxis in response to MIP-1 (data not shown). Since myeloma GGA, and the probe CAAGCCACCCACTGCCTCCCAG. Expression of c-maf
cells from many patients produce MIP-1 (Abe et al., 2002; was detected with the forward primer GCTTCCGAGAAAACGGCTC, the
reverse primer TGCGAGTGGGCTCAGTTATG, and the probe CGACAACCCUneda et al., 2003), it may be interesting to investigate whether
GTCCTCTCCCGAGTTT. The level of c-maf and integrin 7 mRNA was deter-c-maf regulates autocrine stimulation by MIP-1 by upregulat-
mined by normalization to the level of the control gene USF2, which showeding CCR1.
little variance in expression across all myeloma cell lines assayed.
Our observation that c-maf is overexpressed in roughly half
of myeloma cases is surprising given the low frequency of c-maf Cell culture, retroviral constructs, and transduction
translocations (5%–10%) in myeloma and MGUS (Fonseca et Cell lines were maintained in RPMI-1640 (GIBCO-BRL) or ACL-4 (GIBCO-
BRL) with 10% fetal calf serum (HyClone) and penicillin/streptomycinal., 2002; Kuehl and Bergsagel, 2002). It will therefore be inter-
(GIBCO-BRL). Bone marrow stroma was obtained from aspirates of healthyesting to determine the mechanism by which c-maf is overex-
donors and cultured as previously described (Uchiyama et al., 1993). Bicis-pressed in cases where no translocation involving the IgH locus
tronic retroviral constructs were generated using the VxyPuro backbone
was detected. Previous studies have investigated whether the (Shaffer et al., 2000) or the vEGFP-F backbone (Davis et al., 2001) that
expression of c-maf in myeloma cell lines is biallelic or monoal- allow for expression of a cDNA and the puromycin resistance gene or a
lelic (Chesi et al., 1998). In two cell lines that contained a c-maf farnesylated EGFP protein, respectively. Infections were carried out as de-
scribed (Shaffer et al., 2000), and cells receiving VxyPuro constructs weretranslocation, the expression of c-maf was only detected from
maintained in puromycin (1 g/ml). The VxyPuro-cmaf construct containedthe translocated allele. However, in the case of LP-1, a cell line
a human c-maf cDNA, corresponding to sequences from 804 to 2005that expresses c-maf without a t(16:14) translocation, c-maf
with respect to the translation start site. The VxyPuro-Ac-maf and vEGFP-expression was detected from both alleles (Chesi et al., 1998).
Ac-maf constructs were made by fusing a FLAG-tagged acidic extension to
This observation is consistent with a transcriptional activation the leucine zipper portion of c-maf,1753 to2005, as previously described
of c-maf in some multiple myelomas by a currently unknown (Olive et al., 1997). To determine the effect of dominant negative c-maf
on cell number, myeloma cells were infected with a vEGFP-F retrovirusmechanism(s).
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Anderson, K.C. (2001). Multiple myeloma. Advances in disease biology:expressing dominant negative c-maf or a control vEGFP-F retrovirus, and
therapeutic implications. Semin. Hematol. 38, 6–10.EGFP positive cells were enumerated by flow cytometry as described (Davis
et al., 2001). Bellamy, W.T., Richter, L., Frutiger, Y., and Grogan, T.M. (1999). Expression
of vascular endothelial growth factor and its receptors in hematopoietic
Cyclin D2 promoter analysis malignancies. Cancer Res. 59, 728–733.
Myeloma cell lines were cotransfected with an expression vector (pCMV-
Bergsagel, P.L., Chesi, M., Nardini, E., Brents, L.A., Kirby, S.L., and Kuehl,Script; Stratagene) containing the c-maf cDNA, a reporter vector in which
W.M. (1996). Promiscuous translocations into immunoglobulin heavy chainthe human cyclin D2 promoter drives expression of luciferase (Shaffer et al.,
switch regions in multiple myeloma. Proc. Natl. Acad. Sci. USA 93, 13931–
2000), and a control -Gal expressing plasmid, as described (Shaffer et al.,
13936.
2000). Luciferase activity was measured using a luminometer and levels
Chesi, M., Bergsagel, P.L., Shonukan, O.O., Martelli, M.L., Brents, L.A.,were normalized to -Gal expression. Site directed mutagenesis with the
Chen, T., Schrock, E., Ried, T., and Kuehl, W.M. (1998). Frequent dysregula-mutant cyclin D2 primers, GGGGAGGACCGGgtaGAGTtAGtacGCCCCGA
tion of the c-maf proto-oncogene at 16q23 by translocation to an Ig locusGGC and GCCTCGGGGCgtaCTaACTCtacCCGGTCCTCCCC, was pre-
in multiple myeloma. Blood 91, 4457–4463.formed using the QuickChange kit (Stratagene).
Cook, G., Dumbar, M., and Franklin, I.M. (1997). The role of adhesion mole-
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